Granules News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Granules India Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Granules India Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Granules from all sources in a single place.

Granules India Ltd.

20 Apr 2026

689.45

0.36%

Granules India

Buy: Granules India Ltd.

Target

ICICI Direct

Number of FII/FPI investors increased from 209 to 241 in Mar 2026 qtr.

Granules India Ltd.

16 Apr 2026

689.45

0.36%

Company Update

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Schedule of Analyst/Investors Earnings Conference call of the Company for Q4 and the financial year ended on March 31, 2026

pdf

Granules India Ltd.

16 Apr 2026

689.45

0.36%

Board Meeting

Granules India Ltd-$ - 532482 - Board Meeting Intimation for Inter-Alia, To Consider And Approve The …

BSE India

Granules India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2026 ,inter alia, to consider and approve the audited financial results for the fourth quarter and financial year ended on March 31, 2026 and the recommendation of final dividend for FY 2025-26, if any.

pdf

Granules India Ltd.

09 Apr 2026

689.45

0.36%

Granules India to tighten oversight after US FDA warning, exec says

Business Line

Granules India, which is globally one of the largest paracetamol makers and a major player in the active pharmaceutical ingredients market, derives a bulk of its revenue from the US

Granules has gained 45.13% in the last 1 Year

Granules India Ltd.

08 Apr 2026

689.45

0.36%

Corp. Note

Granules India Ltd-$ - 532482 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGranules India Ltd- 2CIN NO.L24110TG1991PLC012471 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NONE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: CHAITANYA TUMMALA Designation: COMPANY SECRETARY EmailId: Chaitanya.tummala@granulesindia.com Name of the Chief Financial Officer: Mukesh Surana Designation: Chief Financial Officer EmailId: Mukesh.surana@granulesindia.com Date: 08/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Granules India Ltd.

04 Apr 2026

689.45

0.36%

Company Update

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Granules India Ltd.

31 Mar 2026

689.45

0.36%

Granules Life Sciences' facility gets VAI classification from USFDA

Business Line

This development enhances Granules India's finished dosage manufacturing by enabling multi-site production for approved products, according to Chairman Krishna Prasad Chigurupati

ICICI Direct increased Buy price target of Granules India Ltd. to 770.0 on 20 Apr, 2026.

Granules India Ltd.

31 Mar 2026

689.45

0.36%

Company Update

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Granules India Ltd.

31 Mar 2026

689.45

0.36%

Underappreciated US model; multiple optionalities in play

Buy: Granules India Ltd.

Target

Emkay

We initiate coverage of Granules with BUY and SOTP-based Mar-27 TP of Rs800 (implied target EV/EBITDA of ~12x; ~30% upside). Granules fits into our framework of backing companies with a smaller US base + a US portfolio construct with strong near-term growth visibility.